HighTower Advisors’s Zentalis Pharmaceuticals ZNTL Stock Holding History

HighTower Advisors’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-29,905	Closed	-$453K	–	4069
2023 Q4	$453K	Hold	29,905	–	–	﹤0.01%	2399
2023 Q3	$600K	Hold	29,905	–	–	﹤0.01%	2107
2023 Q2	$844K	Hold	29,905	–	–	﹤0.01%	1858
2023 Q1	$514K	Sell	29,905 -269	-0.9%	-$5.45K	﹤0.01%	2087
2022 Q4	$607K	Buy	30,174 +247	+0.8%	+$5.31K	﹤0.01%	1991
2022 Q3	$648K	Sell	29,927 -291	-1%	-$7.96K	﹤0.01%	1860
2022 Q2	$848K	Sell	30,218 -25	-0.1%	-$662	﹤0.01%	1733
2022 Q1	$1.4M	Sell	30,243 -19	-0.1%	-$1.02K	﹤0.01%	1574
2021 Q4	$2.54M	Buy	30,262 +357	+1%	+$27.6K	0.01%	1227
2021 Q3	$1.99M	Hold	29,905	–	–	0.01%	1256
2021 Q2	$1.59M	Buy	+29,905	New	+$1.6M	﹤0.01%	1366

Other funds holding ZNTL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

HighTower Advisors's ZNTL Position: Q1 2024 in Review

HighTower Advisors sold out of Zentalis Pharmaceuticals (ZNTL) in Q1 2024, closing a stake of 29,905 shares — an estimated $453K sold.

HighTower Advisors first reported a position in ZNTL in Q2 2021 and held it in 11 quarters. The position peaked at $2.54M in Q4 2021. 142 funds tracked by Wall St. Rank hold ZNTL as of Q1 2024.

HighTower Advisors reported no remaining Zentalis Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
HighTower Advisors sold 29,905 Zentalis Pharmaceuticals shares in Q1 2024, an estimated $453K.
HighTower Advisors first reported a position in Zentalis Pharmaceuticals in Q2 2021 and held it in 11 quarters.
HighTower Advisors's Zentalis Pharmaceuticals position peaked at $2.54M in Q4 2021.
142 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2024.

Based on HighTower Advisors's 13F filing for Q1 2024, filed 6 May 2024.